A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Curis, Inc.
ClinicalTrials.gov Identifier:
NCT00728793
First received: August 1, 2008
Last updated: November 17, 2011
Last verified: November 2011

August 1, 2008
November 17, 2011
August 2008
April 2010   (final data collection date for primary outcome measure)
To establish the maximum tolerated dose (MTD) for CUDC-101 and to assess the safety and tolerability of CUDC-101 in subjects with advanced and refractory solid tumors. [ Time Frame: Study treatment period ] [ Designated as safety issue: Yes ]
To establish the maximum tolerated dose (MTD) for CUDC-101 and to assess the safety and tolerability of CUDC-101 in subjects with advanced and refractory solid tumors.
Complete list of historical versions of study NCT00728793 on ClinicalTrials.gov Archive Site
  • To evaluate the efficacy of CUDC-101 in subjects with advanced and refractory solid tumors. [ Time Frame: Study treatment period ] [ Designated as safety issue: No ]
  • To assess the pharmacokinetics of CUDC-101 in this patient population. [ Time Frame: Study treatment period ] [ Designated as safety issue: No ]
  • To evaluate pharmacodynamic biomarkers of CUDC-101 activity. [ Time Frame: Study treatment period ] [ Designated as safety issue: No ]
  • To evaluate the efficacy of CUDC-101 in subjects with advanced and refractory solid tumors.
  • To assess the pharmacokinetics of CUDC-101 in this patient population.
  • To evaluate pharmacodynamic biomarkers of CUDC-101 activity.
Not Provided
Not Provided
 
A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors
A Phase I Open-Label, Multiple Dose, Sequential Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced and Refractory Solid Tumors

This is a phase I, open-label, dose-escalation study of CUDC-101 in patients with advanced and refractory solid tumors. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2(Her2) and histone deacetylase (HDAC). The study is designed to establish the safety, including the maximum tolerated dose, the pharmacokinetics, and the anti-tumor activity of CUDC-101.

Not Provided
Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Tumors
Drug: CUDC-101
Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
April 2010
April 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects with advanced, refractory solid tumors and a histopathologically confirmed diagnosis
  • Subjects must have no further standard of care options or have refused standard therapy
  • Measurable or evaluable disease
  • Age ≥ 18 years
  • ECOG performance < 2
  • Life expectancy ≥ 3 months
  • If female, neither pregnant or lactating
  • If of child bearing potential, must use adequate birth control
  • Absolute neutrophil count ≥ 1,500/µL; platelets ≥ 100,000/µL;
  • Creatinine ≤ 1.5x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60mL/min/1.73m2
  • Total bilirubin ≤ 1.5x ULN; AST/ALT ≤ 2.5x ULN. In subjects with documented liver metastases, the AST/ALT may be ≤ 5x ULN
  • Prothrombin time ≤1.5x ULN, unless receiving therapeutic anticoagulation
  • Serum magnesium and potassium within normal limits (may be supplement to achieve normal values)
  • Subjects with brain metastases are eligible if controlled on a stable dose ≤ 10mg prednisone/day or its equivalent dose of steroids
  • Able to render informed consent and to follow protocol requirements.

Exclusion Criteria:

  • Anticancer therapy within 4 weeks of study entry. Prostate cancer subjects on LHRH hormonal therapy may be enrolled and continue on this therapy.
  • Use of investigational agent(s) within 30 days of study entry
  • History of cardiac disease with a New York Heart Association (NYHA) Class II or greater congestive heart failure (CHF), myocardial infarction (MI) or unstable angina in the past 6 months prior to Day 1 of treatment, serious arrhythmias requiring medication for treatment.
  • Known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C.
  • The following are permitted but should be used with caution and other suitable agents used if possible:

    • Subjects receiving concomitant medications metabolized by CYP 3A4 and CYP 2D6
    • CYP3A4 inducers
    • CYP3A4 inhibitors
    • Warfarin
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00728793
CUDC-101-101
No
Curis, Inc.
Curis, Inc.
Not Provided
Principal Investigator: Anthony Tolcher, M.D. START (South Texas Accelerated Research Therapeutics)
Curis, Inc.
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP